Dylan Jovine has launched a new promotional campaign for Behind the Markets featuring an investment linked to “smart chemotherapy.”

By subscribing to Behind the Markets’ monthly advisory service today, you can discover how to potentially make 463% gains on a $4 micro-cap developing “smart chemo” technology.

In our review, you will find everything you need to know about Behind the Markets and today’s new smart chemotherapy investment opportunity.

What is Behind the Markets?

Behind the Markets is a monthly investment advisory service led by Dylan Jovine. It’s the flagship subscription from Behind the Markets, LLC, a Florida-based investment publishing company.

Each month, Dylan Jovine highlights new opportunities for subscribers – including investments he believes could increase in price in the future.

Behind the Markets focuses on the following:

• Mid-cap / medium-term investment opportunities
• Market capitalizations between $1 billion and $10 billion
• Companies that have experienced (what Dylan and his team believe to be) a temporary setback
• Companies with high returns on equity, low debt, and a durable competitive advantage

The goal is to help individual investors outperform more prominent investors. While most institutions focus on Modern Portfolio Theory (which is risk-averse with average returns), Behind the Markets focuses on business valuation, aiming to identify undervalued companies.

By subscribing to Behind the Markets today, you get instant access to monthly issues. Subscribers also receive bonus guides, monthly portfolio updates, 24/7 access to a members-only portal, and other perks.

What Will You Learn From Behind the Markets?

The goal of Behind the Markets is straightforward: to identify undervalued stocks and recommend those stocks to investors, helping investors create long-term value if predictions are correct.

Behind the Markets mostly targets conservative investors seeking long-term value, not day traders or those seeking to get rich quickly.

To help you succeed, Behind the Markets comes with trade alerts, monthly portfolio updates, monthly stock recommendations, and other perks.

Dylan Jovine and his team also recommend specific stocks. Each issue includes investment ideas, including stocks Dylan has thoroughly researched based on his 30+ years of investing experience.

Unlock biotech profits with smart chemo insights—subscribe now!

How Behind the Markets’ Stock Recommendations Work

Behind the Markets aims to identify undervalued stocks. Each month, investors receive a new issue with stock recommendations and reports.

Here’s how Behind the Markets’ stock recommendations work:

Behind the Markets aims to identify companies that, according to Dylan Jovine’s research, are selling at a significant discount based on what the underlying business is worth.

Dylan describes it as a “business valuation” approach to investing. He uses his 30+ years of experience to analyze the value of the underlying business and compares that value to the current stock price in an attempt to find undervalued companies.

Dylan primarily focuses on mid-cap companies with a market cap between $1 and $10 billion.

Most investments are designed for the medium term. They’re not “get rich quick” companies or “buy and hold forever” investments. Instead, they’re somewhere in between.

To limit risk, Dylan aims to find companies that have experienced (what Dylan believes to be) a temporary setback. These companies may have had bad recent news, for example, that affects the stock price while having little impact on the underlying, long-term business. Investors can buy at a good price, giving them a better opportunity to earn extra value.

When you subscribe to Behind the Markets, you can discover which stocks Dylan likes, which businesses he believes are undervalued, and how to apply the business valuation approach to your own investing strategy to potentially outperform institutional investors.

What is the “Smart Chemo” Company?

Dylan has published a report titled Smart Chemo: The Small Biotech Revolutionizing Cancer Treatment as part of a 2024 promotion for Behind the Markets.

By subscribing to Behind the Markets today, regardless of your subscription level, you get instant access to the report.

In the report, Dylan explains crucial details about a company that could change the future of cancer treatment. Some of the ways Dylan teases the company before revealing its name include:

• The Wall Street Journal described the company as offering “a guided missile for cancer.”
• The medical journal Nature described the company’s advances as “the dawn of a new era against cancer.”
• The FDA fast-tracked approval for the tiny biotech company that developed the technology.
• Dylan’s research suggests investors could earn 463% gains by investing in the biotech company today.
• The company is currently considered a micro-cap company and is available for just $4 today.

We can’t reveal the company’s name and ticker symbol upfront. However, by subscribing to Behind the Markets today, you can discover everything you need to know about the company and how its dramatic technology works.

Discover the $4 micro-cap set to revolutionize cancer treatment!

How Smart Chemo Works

The company mentioned above has developed something called “smart chemo.”

Typically, oncologists recommend treating some of the world’s deadliest cancers with chemotherapy.

Chemotherapy, however, is like a shotgun: it blasts all cells, including healthy cells and cancer kills, in an attempt to eradicate cancer from the body. That’s why chemotherapy is associated with awful side effects.

However, the company mentioned above has developed “smart chemo” that only attacks cancer cells while ignoring healthy cells.

Here’s how Dylan Jovine explains the smart chemo technology and its potential impact:

“The new ‘smart chemo’ attacks just the cancer cells – and leaves the healthy ones alone. If that sounds like science fiction, consider this – The largest drug companies are scrambling to invest billions of dollars into this new ‘Smart Chemo.’”

In fact, Dylan claims some of the world’s largest pharmaceutical companies have already invested billions into smart chemo. Pfizer has invested $43 billion, Merck has invested $4 billion, Bristol-Myers has invested $8.4 billion, and AbbVie Inc. has invested $10.1 billion.

All of these pharmaceutical companies believe in the technology because, as Dylan claims, it could “eliminate” chemotherapy side effects:

“This treatment will not just change medicine…it has the potential to eliminate side effects from cancer treatment.”

The company’s current market cap is $363 million, making it a micro-cap. Morgan Stanley, however, believes it will grow into a $140 billion market.

Dylan Previously Recommended a “Smart Chemo” Company Called Immunogen for 430% Gains.

This isn’t the first time Dylan has spotted an investment opportunity linked to “smart chemotherapy” technology. Dylan claims this latest investment opportunity reminds him of a previous investment recommendation for Immunogen:

• On July 6, 2024, Dylan Jovine recommended buying Immunogen, which was valued at $5.30 per share at the time. Eighteen months later, AbbVie acquired Immunogen for $31.26 per share, delivering 430% gains to investors.

Dylan was impressed with the returns. However, he claims that the use of Immunogen could have risen by 1,000% if it hadn’t been acquired. That’s how valuable the innovative chemotherapy technology was.

Ready for 463% gains? Learn about smart chemo stocks today!

Who is Dylan Jovine?

Dylan Jovine is an investor with 30+ years of experience on and off Wall Street.

Dylan began his career on Wall Street in 1991. Instead of working for a major institution, he worked with legendary New York investor Peter Jacquith. Dylan explains that Peter was the only one willing to give a chance to an “outsider” like Dylan.

On Wall Street, Dylan grew a reputation for picking stocks – particularly stocks before they were acquired. At 24 years old, Dylan started his own brokerage firm. He became one of the youngest in US history to launch his registered broker-dealer and market maker.

In 2013, Dylan left his brokerage and decided to take time off. He then entered the financial publishing space.

Today, Dylan is the founder and CEO of Behind the Markets, LLC. The investment publishing company offers several newsletters catered to individual investors, including its flagship publication, Behind the Markets.

Dylan Has a Proven Track Record of Picking Biotech Winners

Dylan is a big fan of biotech investing.

By subscribing to Behind the Markets today, you get immediate access to a bundle of bonus reports featuring the latest opportunities in biotech – including opportunities related to cancer treatment, weight loss drugs, and more.

Dylan is confident his biotech recommendations are solid because he has a history of picking winners in biotech:

“During the almost thirty years I’ve been doing this, I’ve earned a reputation for being ahead of the trend. You saw some of the exceptional picks I’ve made throughout my career. And I took those skills to Behind the Markets.”

Here are some of Dylan’s biggest winners in the biotech investing space:

• ChemoCentrix rose 435% after Dylan recommended buying it
• Krystal Biotech jumped 275%
• Array Biopharma moved 144%
• Kura Oncology rose 124%
• Casi Pharmaceuticals jumped 129%

Today, Dylan believes his newly identified “smart chemo” company could be a similar winner.

Uncover the biotech stock poised to soar 463%—join Behind the Markets!

Dylan Invests Based on FDA Approval Stages

Why is Dylan so confident about his biotech investing record? Dylan’s ability to understand FDA approval stages better than competing investors gives him an advantage.

Investing in companies too early in the FDA approval cycle carries too much risk. Many companies begin this process and are never heard from again.

If you invest in companies too late in the FDA approval cycle, you risk missing gains. The market has already discovered these well-known companies.

Instead, Dylan recommends investing in biotech companies at the perfect phase – right in the middle of Phase 3 trials:

“Find a company with a safe drug that can impact a massive market that’s in Phase 3 trials – and generational wealth can be made. That’s where we’ve had most of our success.”

These companies are close to entering the market with a powerful and popular drug—and they’ve created a drug that appears to be safe.

FDA approval phases include:

Phase 1 Trial) Small patient study to analyze safety and dosing of medication.

Phase 2 Trial) A more extensive study with more patients is used to assess efficacy and safety further.

Phase 3 Trial) The largest study has confirmed that the drug is safe and effective. The drug is compared to current treatments and analyzed for side effects.

Most drugs (63.2% of all drugs, according to Dylan’s research) never make it past Phase 1. Unfortunately, this is also the phase where many people promote these stocks, declaring them the “next big thing” in medicine.

By subscribing to Behind the Markets today, you can discover the “smart chemo” drug that’s at the perfect investing point, according to Dylan’s research. In fact, he claims it’s his #1 smart chemo drug for 2024.

Learn how to profit from groundbreaking cancer treatment—start today!

Dylan’s #1 Smart Chemo Stock for 2024

Using his 30+ years of experience and his history of biotech investing, Dylan claims to have identified the #1 smart chemo stock for 2024.

This is the same $4 micro-cap company mentioned above. Dylan believes it could soar to record highs as its chemo drug continues to develop.

Although we can’t reveal the name and ticker symbol of the chemo stock upfront, Dylan reveals it to all new Behind the Markets subscribers. You get immediate access to the Smart Chemo: The Small Biotech Revolutionizing Cancer Treatment report after subscribing to Behind the Markets.

Here are some of the things we do know about the #1 chemo stock upfront:

One small company owns a patent related to “smart chemo” technology.

That stock “could hand investors 5, 10, 20, even 50 times their money,” according to Dylan’s research.

Dylan is so confident in this stock that he claims, “If you were to make only one investment in the next decade, this is it.”

The company is at the forefront of the “smart chemo” trend, which involves targeting specific cancer cells with chemotherapy. Today’s chemotherapy treatments attack all cells, including healthy cells and cancer cells.

Dylan believes the company is “remarkable – yet overlooked.” Despite being at the forefront of the smart chemo trend, the company isn’t a mainstream name for investors, which is why Dylan believes it’s worth buying.

The stock is available for as little as $4 per share today (it has fluctuated between $4 and $7 per share for the past few months).

By subscribing to Behind the Markets today, you get immediate access to the name and ticker symbol of the biotech stock.

Dylan Jovine reveals the $4 stock that could skyrocket—find out now!

What’s Included with Behind the Markets?

All new subscriptions to Behind the Markets come with a bundle of bonus reports and guides.

Here’s what you get when you subscribe to Behind the Markets today:

• Monthly Issues of Behind the Markets with Stock Picks: Each month, you get stock picks from Dylan Jovine based on his 30 years of investing experience. Dylan aims to identify undervalued companies – including companies that have recently experienced a setback – to help individual investors outperform larger ones. Your annual subscription includes 12 issues of Behind the Markets emailed directly to your inbox.
• 24/7 Access to Members-Only Portfolio: All Behind the Markets subscribers get 24/7 access to a members-only portfolio. You can see which trades Dylan has recommended in the past, how those trades have performed over time, the buy and sell date, and more. If you want to make the same investing returns as Dylan and other Behind the Markets subscribers, then the model portfolio can help.
• Monthly Research Report: Dylan publishes at least one new research report each month. The report may cover a trending investing topic, such as chipmakers or artificial intelligence. Dylan breaks down the topic into further detail while also providing investment ideas, stock recommendations, and other information.
• Trade Updates & Alerts: If Dylan spots an opportunity in the markets between monthly issues, he may issue a trade update or alert. If a stock in the model portfolio, for example, is making moves, Dylan may recommend buying more of it or selling it.
• Weekly Stock Newsletters: All Behind the Markets subscriptions come with three bonus weekly newsletter subscriptions. Those newsletter subscriptions cover trending stocks in the investing world – including stocks notable investors are buying, stocks that institutions are buying, and stocks insiders are buying (based on publicly disclosed reports). The three weekly bonus newsletters include the following:
  • 3 Stocks Legends Are Buying
  • 3 Stocks Wall Street is Buying
  • 3 Stocks Insiders Are Buying
• Free Bonus Report: Smart Chemo: The Small Biotech Revolutionizing Cancer Treatment: Dylan has identified a company—currently trading for around $4—that is developing a “smart chemo” technology. That company’s technology could change the future of medicine and healthcare. Dylan values the report at $997. It’s yours to keep even if you cancel your Behind the Markets subscription.
• 24/7 Access to Members-Only Website: Your subscription includes unlimited access to the Behind the Markets members-only area. You can access the latest reports from this area, get the newest issue of Behind the Markets, and get all other perks linked to your subscription.
• 30-Day Moneyback Guarantee: Unhappy with Behind the Markets for any reason? Request a refund within 30 days of your purchase. You can even keep all bonus reports and digital guides as a reward for trying Behind the Markets.
• 3 to 6 Additional Bonus Reports: If you subscribe to Behind the Markets at the $99 per year tier (Great Offer or Best Offer), you get immediate access to 3 bonus reports (with the Great Offer) or six bonus reports (with the Best Offer). Those bonus reports include:
• Free Bonus Report #1: Cut & Paste: The Small Company Revolutionizing Medicine: Dylan has identified one promising biotech company that aims to “cut and paste” disease from the human body. In this report, you can discover full details about this investment opportunity. Dylan likes biotech companies with a strong patent, a strategic partner, and a history of surviving at least one patent challenge. This company has all three features.
• Free Bonus Report #2: Drug Smuggler: 4 Companies Using Radical Methods to Fight Alzheimer’s, Parkinson’s, & Dementia: In another biotech report, Dylan has identified four companies – including publicly traded firms – innovating to fight some of the world’s deadliest diseases. These companies are developing treatments for Alzheimer’s, Parkinson’s disease, and dementia, among other major killers. Like other biotech recommendations, these companies meet Dylan’s required characteristics for investing in a biotech stock.
• Free Bonus Report #3: The ‘King Kong’ of New Drugs: 3 Companies at the Forefront of the Weight Loss Revolution: Weight loss drugs are a multibillion-dollar industry. They solve one of the biggest problems in the world today. In this bonus report, Dylan has identified three companies that could be making the next Ozempic, Wegovy, or Zepbound. These companies are actively developing powerful weight loss drugs that could change the world.
• Free Bonus Report #4: End of Disease: The AI Company Revolutionizing Medicine: Some companies are developing healthcare solutions at the intersection of artificial intelligence and medicine. In this bonus report, you can discover how one AI company could end disease using the power of artificial intelligence.
• Free Bonus Report #5: Biotech Income: How to Generate Monthly Income from Your Biotech Portfolio: Some biotech stocks pay dividends. Others generate income for investors in other ways. Dylan is a big fan of biotech investing, and in this guide, he explains how investors can earn income through biotech investing. You can generate monthly returns while holding a portfolio of promising biotech stocks.
• Free Bonus Report #6: 3 Ingredients to Great Biotech Stocks: Dylan uses a formula of 3 “ingredients” to assess biotech stocks. As mentioned above, those three ingredients include a strong patent, a strategic partner, and a history of defending the patent at least once. In this guide, Dylan explains all three ingredients and why he believes they are essential.
• US-Based Customer Service: Dylan describes his customer service team as more than just a customer service team: they’re a “VIP concierge service” that can help you Monday through Friday from 10 am to 7 pm. The South Carolina-based team is available by phone or online form.

Don’t miss out on the next big biotech revolution—subscribe today!

How Much Does Behind the Markets Cost?

Behind the Markets normally costs $196 to $399 per year, depending on your subscription tier.

However, as part of a 2024 promotion, Dylan Jovine and his team have reduced the price to as little as $49 per year. Plus, the highest-tier subscription (Best Offer) is priced the same as the medium-tier subscription (Great Offer), but it comes with extra perks.

Here’s how pricing works when signing up for Behind the Markets today:

Good Offer ($49 Per Year)

• Immediate access to Behind the Markets
• All other membership perks (model portfolio, trade updates, weekly newsletters, etc.)
• Free bonus report: Smart Chemo: The Small Biotech Revolutionizing Cancer Treatment
• 30-day moneyback guarantee

Great Offer ($99 Per Year)

• Immediate access to Behind the Markets
• Free bonus report: Smart Chemo: The Small Biotech Revolutionizing Cancer Treatment
• All other membership perks (model portfolio, trade updates, weekly newsletters, etc.)
• Three free bonus reports, including:
• Free Bonus Report #1: Cut & Paste: The Small Company Revolutionizing Medicine:
• Free Bonus Report #2: Drug Smuggler: 4 Companies Using Radical Methods to Fight Alzheimer’s, Parkinson’s, & Dementia
• Free Bonus Report #3: The ‘King Kong’ of New Drugs: 3 Companies at the Forefront of the Weight Loss Revolution:
• 30-day moneyback guarantee

Best Offer ($99 Per Year)

• Immediate access to Behind the Markets
• Free bonus report: Smart Chemo: The Small Biotech Revolutionizing Cancer Treatment
• All other membership perks (model portfolio, trade updates, weekly newsletters, etc.)
• Six free bonus reports, including:
• Free Bonus Report #1: Cut & Paste: The Small Company Revolutionizing Medicine:
• Free Bonus Report #2: Drug Smuggler: 4 Companies Using Radical Methods to Fight Alzheimer’s, Parkinson’s, & Dementia
• Free Bonus Report #3: The ‘King Kong’ of New Drugs: 3 Companies at the Forefront of the Weight Loss Revolution:
• Free Bonus Report #4: End of Disease: The AI Company Revolutionizing Medicine:
• Free Bonus Report #5: Biotech Income: How to Generate Monthly Income from Your Biotech Portfolio:
• Free Bonus Report #6: 3 Ingredients to Great Biotech Stocks
• 30-day moneyback guarantee

Turn smart chemo into smart gains—get your Behind the Markets subscription now!

Behind the Markets Refund Policy

Behind the Markets offers a 30-day moneyback guarantee. If you’re unhappy with your subscription for any reason, you can request a refund within 30 days. Plus, you can keep any digital products you receive as a reward for trying the subscription.

Contact Behind the Markets, LLC

You can contact Behind the Markets, LLC, and the company’s US-based customer service team via the following:

• Telephone: 1-800-851-1965
• Online Form: https://behindthemarkets.com/contact-us/
• Mailing Address: 4260 NW 1st Avenue, Suite #55, Boca Raton, FL 33431-4264

Customer service is available Monday to Friday from 10 am to 7 pm EST.

Final Word

Dylan Jovine has spotted a biotech company offering a “smart chemotherapy” technology.

According to Dylan’s research, that company could rise 430% or more as its smart chemo drug takes off.

By subscribing to Behind the Markets today, you get immediate access to a bonus report featuring the name and ticker symbol of the company. Plus, all new subscriptions come with up to 6 other bonus reports, access to a model portfolio, 1 to 2 new stock recommendations per month, and other perks.

To learn more about Behind the Markets or to subscribe to the newsletter today, visit the official website.